SCHEMBL1576811

SCHEMBL1576811

CC(=O)N(Cc1ccccc1)[C@H](COCc1ccccc1)C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
SLC1A1 P43005 1/20 0.44
MAOB P27338 1/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
HSD17B10 Q99714 1/20 0.41
EPOR P19235 1/20 0.41
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
TSPO P30536 1/20 0.40
CA4 P22748 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28137098 0.86 MEN1 (0.44) ALOX5PTGS1PTGS2MEN1KMT2A
SCHEMBL1577179 0.86 MEN1 (0.44) ALOX5PTGS1PTGS2MEN1KMT2A
SCHEMBL19138470 0.84 SLC1A1 (0.49) ALOX5SLC1A1MAOBALDH1A1CA1
SCHEMBL1576833 0.83 MEN1 (0.41) ALOX5PTGS1PTGS2MEN1KMT2A
SCHEMBL1576866 0.81 KMT2A (0.47) MEN1KMT2AALDH1A1L3MBTL1LMNA
SCHEMBL1895976 0.79 KMT2A (0.45) MEN1KMT2AALDH1A1L3MBTL1LMNA
SCHEMBL7772290 0.78 LMNA (0.52) MEN1KMT2AALDH1A1L3MBTL1LMNA
SCHEMBL19836930 0.75 SLC1A1 (0.51) SLC1A1MAOBKMT2AALDH1A1CA1
SCHEMBL6813227 0.75 KMT2A (0.54) ALOX5PTGS1PTGS2MEN1KMT2A
SCHEMBL19836929 0.75 SLC1A1 (0.51) SLC1A1MAOBKMT2AALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 US claimed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 US claimed
EP-2480524-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF Cadila Healthcare Limited (IN) 2012-08-01 EP claimed
WO-2011039781-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-04-07 WO claimed
US-9242926-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2016-01-26 US disclosed
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 US disclosed
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2014-10-02 US disclosed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 US disclosed
EP-2480524-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF Cadila Healthcare Limited (IN) 2012-08-01 EP disclosed
WO-2011039781-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA ALOX5 1446/4885PTGS1 2129/4885PTGS2 1860/4885
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA ALOX5 1446/4885PTGS1 2129/4885PTGS2 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.